CNTY 107
Alternative Names: CNTY-107; Nectin4-targeting IPSC-derived cell therapy - Century TherapeuticsLatest Information Update: 13 Apr 2024
At a glance
- Originator Century Therapeutics
- Class Antineoplastics; Immunotherapies; Induced pluripotent stem cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 09 Apr 2024 Preclinical trials in Solid tumours in USA (Parenteral) prior to April 2024
- 09 Apr 2024 Interim pharmacodynamics data from a preclinical studies in Solid tumour released by Century Therapeutics
- 17 Nov 2022 Early research is underway in Solid tumours in USA (Parenteral) prior to November 2022